Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 145 No. 4950 (2015)

Trends in incidence of oesophageal and gastric cancer according to morphology and anatomical location, in Switzerland 1982–2011

  • Anita Feller
  • Martin Fehr
  • Andrea Bordoni
  • Christine Bouchardy
  • Harald Frick
  • Mohsen Mousavi
  • Annik Steiner
  • Volker Arndt
  • Kerri M. Clough-Gorr
  • The NICER Working Group
Cite this as:
Swiss Med Wkly. 2015;145:w14245


QUESTION UNDER STUDY/PRINCIPLES: This study aimed to evaluate trends in the incidence of oesophageal and gastric cancer by anatomical location and histology using nationally representative Swiss data.

METHODS: We included all oesophageal and gastric cancers recorded in 10 Swiss population-based cancer registries 1982–2011. We calculated age-standardised incidence rates (ASIRs) per 100 000 person-years (PY) (European standard) for both cancer sites stratified by sex, language region (German, French-Italian), morphology and anatomical location. To assess time trends, we estimated annual percentage changes (APCs) with 95% confidence intervals (95% CIs).

RESULTS: ASIR of oesophageal adenocarcinoma increased in both sexes and language regions (p <0.001). The steepest increase occurred in males of the German-speaking region (APC 6.8%, 95% CI 5.8–7.8) with ASIRs of 0.8 per 100,000 PY in 1982–1987 and 3.9 per 100.000 PY in 2007–2011. Incidence of oesophageal squamous cell carcinoma decreased significantly in males of both language regions by around –1.5% per year. In contrast, a slight but significant increase (APC 1.4%, 95% CI 0.3–2.4]) of oesophageal squamous cell carcinoma was observed in females of the German-speaking region. We observed stable rates for cancer of the gastric cardia. The incidence of noncardia gastric cancer decreased substantially in both sexes and language regions (p <0.001).

CONCLUSION: In Switzerland, the incidence of oesophageal adenocarcinoma has risen whereas incidence of noncardia gastric cancer has decreased substantially as observed in other developed countries.


  1. Spitale A, Feller A, Lorez M. Trends in stomach cancer survival in Switzerland. Swiss Cancer Bulletin. 2013;3:241–6.
  2. Ruhstaller T, Arndt V, Lorez M. Trends in survival from oesophageal cancer in Switzerland Swiss Cancer Bulletin. 2014;3:227–31.
  3. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83(10):2049–53.
  4. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995. Int J Cancer. 2002;99(6):860–8.
  5. Bollschweiler E, Holscher AH. Carcinoma of the esophagus – actual epidemiology in Germany. Onkologie. 2001;24(2):180–4.
  6. Aragones N, Izarzugaza MI, Ramos M, Chirlaque MD, Almar E, Martinez C, Oesophago-gastric Cancer Working Group. Trends in oesophago-gastric cancer incidence in Spain: analysis by subsite and histology. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2010;21(Suppl 3):iii69–75.
  7. Brewster DH, Fraser LA, McKinney PA, Black RJ. Socioeconomic status and risk of adenocarcinoma of the oesophagus and cancer of the gastric cardia in Scotland. Br J Cancer. 2000;83(3):387–90.
  8. Gajperia C, Barbiere JM, Greenberg D, Wright K, Lyratzopoulos G. Recent incidence trends and sociodemographic features of oesophageal and gastric cancer types in an English region. Alimentary pharmacology & therapeutics. 2009;30(8):873–80.
  9. Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008;103(11):2694–9.
  10. Newnham A, Quinn MJ, Babb P, Kang JY, Majeed A. Trends in the subsite and morphology of oesophageal and gastric cancer in England and Wales 1971–1998. Alimentary pharmacology & therapeutics. 2003;17(5):665–76.
  11. Powell J, McConkey CC. The rising trend in oesophageal adenocarcinoma and gastric cardia. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation. 1992;1(3):265–9.
  12. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol. 2000;29(4):645–54.
  13. Castro C, Bosetti C, Malvezzi M, Bertuccio P, Levi F, Negri E, La Vecchia C, Lunet N. Patterns and trends in esophageal cancer mortality and incidence in Europe (1980–2011) and predictions to 2015. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2014;25(1):283–90.
  14. Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol. 2001;30(6):1415–25.
  15. Drahos J, Wu M, Anderson WF, Trivers KF, King J, Rosenberg PS, et al. Regional variations in esophageal cancer rates by census region in the United States, 1999–2008. PloS One. 2013;8(7):e67913.
  16. Bosetti C, Levi F, Ferlay J, Garavello W, Lucchini F, Bertuccio P, et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer. 2008;122(5):1118–29.
  17. Hurschler D, Borovicka J, Neuweiler J, Oehlschlegel C, Sagmeister M, Meyenberger C, Schmid U. Increased detection rates of Barrett’s oesophagus without rise in incidence of oesophageal adenocarcinoma. Swiss Med Wkly. 2003;133(37-38):507–14.
  18. Levi F, Randimbison R, La Vecchia C. Esophageal and gastric carcinoma in Vaud, Switzerland, 1976-1994. Int J Cancer Journal. 1998;75(1):160–1.
  19. Schmassmann A, Oldendorf MG, Gebbers JO. Changing incidence of gastric and oesophageal cancer subtypes in central Switzerland between 1982 and 2007. Eur J Epidemiol. 2009;24(10):603–9.
  20. International rules for multiple primary cancers (ICD-O Third Edition). Lyon: International Agency for Research on Cancer (IARC); 2004.
  21. IARCcrgTools – check and conversion programs for cancer registries. 2.05 ed: International Association of Cancer Registries (IACR); 2005.
  22. Data and methods – Cancer Incidence and Mortality in Switzerland by NICER: National Institute for Cancer Epidemiology and Registration (NICER); [09/12/2014]. Available from:
  23. Surveys, Sources – Cancer epidemiology – Data and methods Neuchâtel: Swiss Federal Statistical Office (SFO); [23/10/2015]. Available from:
  24. Doll R, Cook P. Summarizing indices for comparison of cancer incidence data. Int J Cancer. 1967;2(3):269–79.
  25. Armstrong RW, Borman B. Trends in incidence rates of adenocarcinoma of the oesophagus and gastric cardia in New Zealand, 1978–1992. Int J Epidemiol. 1996;25(5):941–7.
  26. Lord RV, Law MG, Ward RL, Giles GG, Thomas RJ, Thursfield V. Rising incidence of oesophageal adenocarcinoma in men in Australia. J Gastroenterol Hepatol. 1998;13(4):356–62.
  27. Otterstatter MC, Brierley JD, De P, Ellison LF, Macintyre M, Marrett LD, Semenciw R, Weir HK. Esophageal cancer in Canada: trends according to morphology and anatomical location. Can J Gastroenterol. 2012;26(10):723–7.
  28. Thomas RJ, Lade S, Giles GG, Thursfield V. Incidence trends in oesophageal and proximal gastric carcinoma in Victoria. Aust N Z J Surg. 1996;66(5):271–5.
  29. Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2012;23(12):3155–62.
  30. Brown LM, Hoover R, Silverman D, Baris D, Hayes R, Swanson GM, et al. Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol. 2001;153(2):114–22.
  31. Pandeya N, Olsen CM, Whiteman DC. Sex differences in the proportion of esophageal squamous cell carcinoma cases attributable to tobacco smoking and alcohol consumption. Cancer Epidemiol. 2013;37(5):579–84.
  32. Ribeiro U, Jr., Posner MC, Safatle-Ribeiro AV, Reynolds JC. Risk factors for squamous cell carcinoma of the oesophagus. Br J Surg. 1996;83(9):1174–85.
  33. Schweizerische Gesundheitsbefragung 2012. Neuchâtel: Federal Statistical Office (FSO), 2013.
  34. Tackling harmful alcohol use – country note Switzerland: Organisation for Economic Cooperation and Development (OECD); [23/07/2015]. Available from:
  35. Gmel G, Kuendig H, Notari L, Gmel C. Suchtmonitoring Schweiz – Konsum von Alkohol, Tabak und illegalen Drogen in der Schweiz im Jahr 2013. Lausanne, Schweiz: 2014.
  36. Cancer in Switzerland – development from 1983–2007. Neuchâtel: Federal Statistical Office (FSO), National Institute for Cancer Epidemiology and Registration (NICER), Swiss Childhood Cancer Registry (SCCR), 2011.
  37. Cook MB, Kamangar F, Whiteman DC, Freedman ND, Gammon MD, Bernstein L, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010;102(17):1344–53.
  38. Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA: a cancer journal for clinicians. 2013;63(4):232–48.
  39. Swiss Health Survey 2012 – Overview. Neuchâtel: Federal Statical Office (FSO), 2013.
  40. Rubenstein JH, Taylor JB. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Alimentary pharmacology & therapeutics. 2010;32(10):1222–7.
  41. Turati F, Tramacere I, La Vecchia C, Negri E. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2013;24(3):609–17.
  42. Hoyo C, Cook MB, Kamangar F, Freedman ND, Whiteman DC, Bernstein L, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol. 2012;41(6):1706–18.
  43. Schwenkglenks M, Marbet UA, Szucs TD. Epidemiology and costs of gastroesophageal reflux disease in Switzerland: a population-based study. Sozial- und Praventivmedizin. 2004;49(1):51–61.
  44. Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol. 2004;159(3):252–8.
  45. Webb PM, Law M, Varghese C, Forman D, Yuan JM, Yu M, et al. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001;49(3):347–53.
  46. Xie FJ, Zhang YP, Zheng QQ, Jin HC, Wang FL, Chen M, et al. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World journal of gastroenterology: WJG. 2013;19(36):6098–107.
  47. Heuberger F, Pantoflickova D, Gassner M, Oneta C, Grehn M, Blum AL, Dorta G. Helicobacter pylori infection in Swiss adolescents: prevalence and risk factors. Eur J Gastroenterol Hepatol. 2003;15(2):179–83.
  48. Sihvo EI, Salminen JT, Ramo OJ, Salo JA. The epidemiology of oesophageal adenocarcinoma: has the cancer of gastric cardia an influence on the rising incidence of oesophageal adenocarcinoma? Scand J Gastroenterol. 2000;35(10):1082–6.
  49. Holster IL, Aarts MJ, Tjwa ET, Lemmens VE, Kuipers EJ. Trend breaks in incidence of non-cardia gastric cancer in the Netherlands. Cancer Epidemiology. 2014;38(1):9–15.
  50. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF, Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265(10):1287–9.
  51. Wang HH, Antonioli DA, Goldman H. Comparative features of esophageal and gastric adenocarcinomas: recent changes in type and frequency. Human Pathology. 1986;17(5):482–7.
  52. El-Serag HB, Mason AC, Petersen N, Key CR. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut. 2002;50(3):368–72.
  53. Carr JS, Zafar SF, Saba N, Khuri FR, El-Rayes BF. Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma. J Gastrointest Cancer. 2013;44(2):143–51.
  54. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006;15(5):872–8.
  55. Olefson S, Moss SF. Obesity and related risk factors in gastric cardia adenocarcinoma. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2015;18(1):23–32.
  56. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014;50(7):1330–44.
  57. Peleteiro B, La Vecchia C, Lunet N. The role of Helicobacter pylori infection in the web of gastric cancer causation. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation. 2012;21(2):118–25.
  58. Heusser R, Noseda G. Rahmenbedingungen für ein wirksames Krebsmonitoring in der Schweiz. Schweizer Krebsbulletin. 2012;32(2):143–8.
  59. Heusser R, Lorez M, Bosshard D, Noseda G. Aufbau eines wirksamen nationalen Krebsmonitorings in der Schweiz: eine Aufgabe von NICER und den kantonalen Krebsregistern. Schweizer Krebsbulletin. 2011;31(3):237–41.
  60. Wegmuller B, Bienlein M. The Swiss health care system. World hospitals and health services: the official journal of the International Hospital Federation. 2007;43(1):10–1.
  61. Frei A, Huntsche E. The Swiss health care system. Eur J Health Econ. 2001;2:76–78.
  62. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142–6.
  63. Li-Qing Y. New endoscopic diagnosis and treatment options for early esophageal cancer. Journal of Gastrointestinal & Digestive System. 2012.

Most read articles by the same author(s)

1 2 > >>